An increase in circulating serum mitochondrial DNA is associated with worse survival in patients with newly diagnosed idiopathic pulmonary fibrosis.
Both body mass index and changes in weight have been linked to 1-year mortality risk in patients with fibrotic interstitial lung disease.
Pirfenidone is currently marketed as Esbriet for the treatment of idiopathic pulmonary fibrosis in adults.
Individuals with HIV were more likely to have interstitial lung abnormalities and findings suspicious for the presence of interstitial lung disease than individuals without HIV.
Use of thrombomodulin alfa for the treatment of acute exacerbation of idiopathic pulmonary fibrosis is not recommended, according to phase 3 clinical trial results.
Patients with idiopathic pulmonary fibrosis are faced with a heavy economic burden, with mean annual costs for admission and inpatient care totaling more than $10,000 per patient.
Altered expression of 14 genes in adults was associated with idiopathic pulmonary fibrosis susceptibility.
Persistent or chronic, but not acute, viral infections significantly increase the risk of developing idiopathic pulmonary fibrosis.